Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jan 1;64(1):89-93.
doi: 10.2169/internalmedicine.2925-23. Epub 2024 Apr 16.

Tumor Lysis Syndrome in a Patient with BRAFV600E Mutated Colon Cancer Treated with Cetuximab and Encorafenib

Shunsuke Kasai  1 , Etsuko Sato  1 , Chikara Sakaguchi  1 , Yasutsuna Sasaki  1
Affiliations
Case Reports

Tumor Lysis Syndrome in a Patient with BRAFV600E Mutated Colon Cancer Treated with Cetuximab and Encorafenib

Shunsuke Kasai et al. Intern Med. .

Abstract

Tumor lysis syndrome (TLS) is a fatal complication associated with chemotherapy. We herein report a case of TLS in a 73-year-old woman with metastatic BRAFV600E mutated colon cancer after she received combined treatment with cetuximab and encorafenib. The serum uric acid, urea nitrogen, and creatinine levels were elevated on day four of the first cycle. The fibrin degradation product (FDP) and D-dimer levels were also high. Diuresis and rasburicase were initiated for TLS, and the laboratory data all normalized on day 8. Thus, the possibility of TLS being induced by targeted drugs in patients with solid tumors, including colorectal cancer, must not be overlooked.

Keywords: BRAF mutation; cetuximab and encorafenib; colorectal cancer; tumor lysis syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors state that they have no Conflict of Interest (COI).

Figures

Figure.
Figure.
Computed tomography (CT) showing the spread of liver metastasis and emergence of ascites. Contrast CT of the liver metastasis (A-C) and plain CT (D). Liver metastasis before laparoscopic right hemicolectomy (A), and after hemicolectomy and before starting pembrolizumab (B). Liver metastasis before initiating cetuximab and encorafenib (C) and 1 month after initiating cetuximab and encorafenib (D).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol 127: 3-11, 2004. - PubMed
    1. Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med 364: 1844-1854, 2011. - PMC - PubMed
    1. Rahmani B, Patel S, Seyam O, et al. . Current understanding of tumor lysis syndrome. Hematol Oncol 37: 537-547, 2019. - PubMed
    1. Benatti P, Gafà R, Barana D, et al. . Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 11: 8332-8340, 2005. - PubMed
    1. Schrock AB, Ouyang CJ, Sandhu J, et al. . Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol 30: 1096-1103, 2019. - PubMed

Publication types

MeSH terms